Sunshine Heart to Present at The Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference

SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Dec 1, 2011) - Sunshine Heart, Inc. (ASX: SHC), today announced that Jeff Mathiesen, Sunshine Heart's Chief Financial Officer, is scheduled to present at Canaccord Genuity's 6^th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference in San Francisco, CA on Tuesday, December 6^th at 9:20AM PST.

A live webcast of the presentation will be available under the Webcast section of the Company's website at www.sunshineheart.com.

About Sunshine Heart^®
Sunshine Heart is a global medical device company committed to the commercialization of the C-Pulse Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-Pulse is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart's pumping load. The Company has completed enrollment of an approved U.S. Food and Drug Administration (FDA) 20 patient feasibility clinical trial with the C-Pulse System. Sunshine Heart is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia. The Company has been listed on the ASX since September 2004. For more information, please visit www.sunshineheart.com.